NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









AAX Biotech AB

AAX Biotech AB

Private
StockholmHealthcare & Life Scienceshttps://www.aaxbiotech.com/

Last Round

VC Round

Feb 19, 2026

Momentum

Top 50%

of companies Caplight tracks

Company Overview

AAX Biotech AB is a biotechnology company that develops proprietary antibody engineering technologies, including Seqitope and Opti-mAb, to improve the performance and developability of next-generation antibody therapeutics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antibody engineeringdrug discoveryantibody optimizationtherapeutic antibodiesbiotech servicesepitope mappingaffinity maturationantibody library screeningprotein engineeringcontract researchCROlab automationbiologics developmentwet labbiotech platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AAX Biotech AB Comps

Public and private peers based on sector, stage, and business model.

AAX Biotech AB comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

AAX Biotech AB Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundFeb 19, 2026
VC RoundOct 2, 2024

Key People

Founding team and executive leadership

Daniel X Johansson

CEO CSO, Chief Scientific Officer

Executive Team

AAX Biotech AB Investors

Notable investors and investment history

AAX Biotech AB investors
InvestorRounds
Trio Impact InvestVC Round
Phase2Phase BiopharmaVC Round
Northislet ABVC Round
Karolinska Institutet HoldingVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 19, 2026

    $555K round led by Trio Impact Invest

AAX Biotech AB Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

AAX Biotech AB Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AAX Biotech AB's valuation, stock price, and market status.

Firmographic Details

HeadquartersStockholm
Employee Range10
Year Founded2020
Last FundingFeb 19, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.